Time Topic
9:30-9:40 Opening Remark
Host
Session 1: Biologics Development - Discovery
9:40-10:40 One-stop Solution for CD3-based T-cell Engager Bi-specific Antibody
Derek Chen, Sr. Director, Biologics Discovery Dept., ProBio

1. Sharing of current bi-specific Ab market trending
2. Discussion of strategies for T-cell engager discovery and evaluation
3. Case study of ROR1/CD3 bi-specific Ab
10:40-11:10 A Novel TIGIT and 4-1BB Bispecific Antibody, ABL112, Exhibits Potent Antitumor Activity Through Dual Immune Checkpoint Modulation
이양순이사 / 에이비엘바이오(주)
11:10-12:10 Multiple Approaches to Accelerate VHH Antibody (Single Domain Antibody) Discovery
Derek Chen, Sr. Director, Biologics Discovery Dept., ProBio

1. Review of strategies for VHH discovery
2. Discussion of features and bottlenecks with each technology
3. Case study of VHH discovery via each platform
12:10-13:30 Lunch and Networking
Session 2: Biologics Development - Preclinical to Commercial
13:30-14:00 HighLight Capital: Strategic Investment Approaches and Opportunities
Jane Tan, Director, HighLight Capital
14:00-15:00 Process Development Toobox to Accelerate DNA-to-IND Path of Challenging Molecules (Bi-specifics, Protein etc.)
Rubin Jiang, Director, Antibody PD& MSAT Department, ProBio

1. Introduction of ProBio's innovative platform - ProBox™
2. How to enhance process efficiency and productivity
3. Practical applications of ProBox™ platform
15:00-15:30 Coffee Break and Networking
15:30-16:00 Winning the Battle from Within
이병철 대표 / (주)카나프테라퓨틱스
16:00-17:00 Cost Reduction Strategies in Late-stage Process Development for Biologics
Rubin Jiang, Director, Antibody PD& MSAT Department, ProBio

1. Key milestones reviewing from initial optimization to commercial production
2. How to reduce the cost of goods
3. Strategies sharing of process characterization
17:00-17:05 Closing Remark
주문경 이사 / 진스크립트 프로바이오 한국 사업부문장

등록 후 확인 메일을 보내드리며,

추후 참가 신청자 선별하여 8/23일내로 확정 메일을 보내드릴 예정입니다.

궁금하신 점은 이메일([email protected])로 문의해주세요.